In 2023, the FDA banned 19 peptides from compounding pharmacies. No specific safety incident. No clear signal. Just a regulatory decision that pushed millions of patients toward gray market suppliers and overseas Frontiers Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab A pharmacovigilance datadriven approach to reveal high fatal adverse events following checkpoint immunotherapy PNAS Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database Scientific Reports